Abstract
A recent article by Ghosh et al. entitled "Optimization of intracerebroventricular streptozotocin dose for the induction of neuroinflammation and memory impairments in rats" provides an important new set of information on neuroinflammation and cognitive deficit in a rat model of sporadic Alzheimer's disease (sAD) based on intracerebroventricular administration of streptozotocin (STZ-icv) in Charles-Foster rats in the early post-treatment period of 21 days. This comment is supposed to supplement the aforementioned manuscript by providing additional perspective on important factors that should be taken into account in the process of optimization of the streptozotocin (STZ) dose for intracerebroventricular treatment, and provides a brief overview of possible sources of variation of experimental results reported by different groups working with STZ-icv rodent models.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barilar JO, Knezovic A, Grünblatt E et al (2015) Nine-month follow-up of the insulin receptor signalling cascade in the brain of streptozotocin rat model of sporadic Alzheimer’s disease. J Neural Transm 122:565–576. https://doi.org/10.1007/s00702-014-1323-y
Barilar JO, Knezovic A, Perhoc AB et al (2020) Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer’s and Parkinson’s disease. J Neural Transm 127:231–250. https://doi.org/10.1007/s00702-020-02152-8
Bart Ellenbroek JY (2016) Rodent models in neuroscience research: is it a rat race? Dis Model Mech 9:1079. https://doi.org/10.1242/dmm.026120
Biswas J, Gupta S, Verma DK et al (2018) Involvement of glucose related energy crisis and endoplasmic reticulum stress: Insinuation of streptozotocin induced Alzheimer’s like pathology. Cell Signal 42:211–226. https://doi.org/10.1016/j.cellsig.2017.10.018
Bloch K, Gil-Ad I, Vanichkin A et al (2017) Intracerebroventricular streptozotocin induces obesity and dementia in lewis rats. J Alzheimers Dis 60:121–136. https://doi.org/10.3233/JAD-161289
Boccardi V, Murasecco I, Mecocci P (2019) Diabetes drugs in the fight against Alzheimer’s disease. Ageing Res Rev 54:100936. https://doi.org/10.1016/j.arr.2019.100936
CaymanChemical product information for streptozotocin (n.d.) https://www.caymanchem.com/pdfs/13104.pdf. Accessed on 3.9.2020
Correia SC, Santos RX, Santos MS et al (2013) Mitochondrial abnormalities in a streptozotocin-induced rat model of sporadic Alzheimer’s disease. Curr Alzheimer Res 10:406–419. https://doi.org/10.2174/1567205011310040006
Dansokho C, Heneka MT (2018) Neuroinflammatory responses in Alzheimer’s disease. J Neural Transm 125:771–779. https://doi.org/10.1007/s00702-017-1831-7
De Felice FG, Lourenco MV, Ferreira ST (2014) How does brain insulin resistance develop in Alzheimer’s disease? Alzheimers Dement 10:S26–S32. https://doi.org/10.1016/j.jalz.2013.12.004
de la Garza-Rodea AS, Knaän-Shanzer S, den Hartigh JD et al (2010) Anomer-equilibrated streptozotocin solution for the induction of experimental diabetes in mice (Mus musculus). J Am Assoc Lab Anim Sci 49:40–44
de la Monte SM, Tong M (2014) Brain metabolic dysfunction at the core of Alzheimer’s disease. Biochem Pharmacol 88:548–559. https://doi.org/10.1016/j.bcp.2013.12.012
Gao Y, Tan L, Yu J-T, Tan L (2018) Tau in Alzheimer’s disease: Mechanisms and therapeutic strategies. Curr Alzheimer Res 15:283–300. https://doi.org/10.2174/1567205014666170417111859
Ghosh R, Sil S, Gupta P, Ghosh T (2020) Optimization of intracerebroventricular streptozotocin dose for the induction of neuroinflammation and memory impairments in rats. Metab Brain Dis. https://doi.org/10.1007/s11011-020-00588-1
Gilles C, Ertlé S (2000) Pharmacological models in Alzheimer’s disease research. Dialogues Clin Neurosci 2:247–255
Grieb P (2016) Intracerebroventricular streptozotocin injections as a model of Alzheimer’s Disease: in search of a relevant mechanism. Mol Neurobiol 53:1741–1752. https://doi.org/10.1007/s12035-015-9132-3
Grünblatt E, Salkovic-Petrisic M, Osmanovic J et al (2007) Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem 101:757–770. https://doi.org/10.1111/j.1471-4159.2006.04368.x
Guo Z, Chen Y, Mao Y-F et al (2017) Long-term treatment with intranasal insulin ameliorates cognitive impairment, tau hyperphosphorylation, and microglial activation in a streptozotocin-induced Alzheimer’s rat model. Sci Rep 7:45971. https://doi.org/10.1038/srep45971
Hampel H, Mesulam M-M, Cuello AC et al (2018) The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain 141:1917–1933. https://doi.org/10.1093/brain/awy132
Heo J-H, Lee S-R, Lee S-T et al (2011) Spatial distribution of glucose hypometabolism induced by intracerebroventricular streptozotocin in monkeys. J Alzheimers Dis 25:517–523. https://doi.org/10.3233/JAD-2011-102079
Hoyer S (2004) Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 490:115–125. https://doi.org/10.1016/j.ejphar.2004.02.049
Hoyer S, Lannert H (2007) Long-term abnormalities in brain glucose/energy metabolism after inhibition of the neuronal insulin receptor: implication of tau-protein. J Neural Transm Suppl 195–202. https://doi.org/10.1007/978-3-211-73574-9_25
Kamat PK, Kalani A, Rai S et al (2016) Streptozotocin intracerebroventricular-induced neurotoxicity and brain insulin resistance: a therapeutic intervention for treatment of sporadic Alzheimer’s Disease (sAD)-like pathology. Mol Neurobiol 53:4548–4562. https://doi.org/10.1007/s12035-015-9384-y
Kellar D, Craft S (2020) Brain insulin resistance in Alzheimer’s disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol 19:758–766. https://doi.org/10.1016/S1474-4422(20)30231-3
Knezovic A, Osmanovic-Barilar J, Curlin M et al (2015) Staging of cognitive deficits and neuropathological and ultrastructural changes in streptozotocin-induced rat model of Alzheimer’s disease. J Neural Transm 122:577–592. https://doi.org/10.1007/s00702-015-1394-4
Knezovic A, Osmanovic Barilar J, Babic A et al (2018) Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s disease. Neuropharmacology 135:48–62. https://doi.org/10.1016/j.neuropharm.2018.02.027
Kraska A, Santin MD, Dorieux O et al (2012) In vivo cross-sectional characterization of cerebral alterations induced by intracerebroventricular administration of streptozotocin. PLoS One 7:e46196. https://doi.org/10.1371/journal.pone.0046196
Lacković Z, Šalković M (1990) Streptozotocin and alloxan produce alterations in rat brain monoamines independently of pancreatic beta cells destruction. Life Sci 46:49–54. https://doi.org/10.1016/0024-3205(90)90056-W
Lester-Coll N, Rivera EJ, Soscia SJ et al (2006) Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer’s disease. J Alzheimers Dis 9:13–33. https://doi.org/10.3233/jad-2006-9102
Mayer G, Nitsch R, Hoyer S (1990) Effects of changes in peripheral and cerebral glucose metabolism on locomotor activity, learning and memory in adult male rats. Brain Res 532:95–100. https://doi.org/10.1016/0006-8993(90)91747-5
Mishra SK, Singh S, Shukla S, Shukla R (2018) Intracerebroventricular streptozotocin impairs adult neurogenesis and cognitive functions via regulating neuroinflammation and insulin signaling in adult rats. Neurochem Int 113:56–68. https://doi.org/10.1016/j.neuint.2017.11.012
Mosconi L (2013) Glucose metabolism in normal aging and Alzheimer’s disease: Methodological and physiological considerations for PET studies. Clin Transl Imaging 1. https://doi.org/10.1007/s40336-013-0026-y
Noble EP, Wurtman RJ, Axelrod J (1967) A simple and rapid method for injecting H3-norepinephrine into the lateral ventricle of the rat brain. Life Sci 6:281–291. https://doi.org/10.1016/0024-3205(67)90157-9
Oles PJ (1978) High-pressure liquid chromatographic separation and determination of anomeric forms of streptozocin in a powder formulation. J Pharm Sci 67:1300–1302. https://doi.org/10.1002/jps.2600670929
Pilipenko V, Narbute K, Pupure J et al (2020) Neuroprotective potential of antihyperglycemic drug metformin in streptozocin-induced rat model of sporadic Alzheimer’s disease. Eur J Pharmacol 881:173290. https://doi.org/10.1016/j.ejphar.2020.173290
PubPeer report (n.d.) Intracerebroventricular injection of citrate inhibits hypothalamic AMPK and modulates feeding behavior and peripheral insulin signaling.” In: PubPeer. https://pubpeer.com/publications/44206BE96B92EA0A0ABEC68D8918D5. Accessed 11 Oct 2020
Reeta KH, Singh D, Gupta YK (2017) Chronic treatment with taurine after intracerebroventricular streptozotocin injection improves cognitive dysfunction in rats by modulating oxidative stress, cholinergic functions and neuroinflammation. Neurochem Int 108:146–156. https://doi.org/10.1016/j.neuint.2017.03.006
Rodrigues MV, Gutierres JM, Carvalho F et al (2019) Protection of cholinergic and antioxidant system contributes to the effect of Vitamin D ameliorating memory dysfunction in sporadic dementia of Alzheimer’s type. Redox Rep 24:34–40. https://doi.org/10.1080/13510002.2019.1617514
Salkovic-Petrisic M, Hoyer S (2007) Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. J Neural Transm Suppl 217–233. https://doi.org/10.1007/978-3-211-73574-9_28
Salkovic-Petrisic M, Knezovic A, Hoyer S, Riederer P (2013) What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer’s disease, about the therapeutic strategies in Alzheimer’s research. J Neural Transm 120:233–252. https://doi.org/10.1007/s00702-012-0877-9
Salkovic-Petrisic M, Osmanovic-Barilar J, Brückner MK et al (2011) Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer’s disease: a long-term follow up study. J Neural Transm 118:765–772. https://doi.org/10.1007/s00702-011-0651-4
Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med 8:595–608. https://doi.org/10.15252/emmm.201606210
Sharma M, Gupta YK (2001) Intracerebroventricular injection of streptozotocin in rats produces both oxidative stress in the brain and cognitive impairment. Life Sci 68:1021–1029. https://doi.org/10.1016/S0024-3205(00)01005-5
Smalheiser NR (2019) Ketamine: a neglected therapy for Alzheimer Disease. Front Aging Neurosci 11:186. https://doi.org/10.3389/fnagi.2019.00186
Stoppa GR, Cesquini M, Roman EA et al (2008) Intracerebroventricular injection of citrate inhibits hypothalamic AMPK and modulates feeding behavior and peripheral insulin signaling. J Endocrinol 198:157–168. https://doi.org/10.1677/JOE-07-0428
STZ protocol for induction of diabetes by the National Institute of Diabetes and Digestive and Kidney Diseases (n.d.) https://www.diacomp.org/shared/showFile.aspx?doctypeid=3&docid=19. Accessed on 3.9.2020
Talbot K, Wang H-Y (2014) The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer’s disease. Alzheimers Dement 10:S12–S25. https://doi.org/10.1016/j.jalz.2013.12.007
Tobore TO (2019) On the central role of mitochondria dysfunction and oxidative stress in Alzheimer’s disease. Neurol Sci 40:1527–1540. https://doi.org/10.1007/s10072-019-03863-x
Wang-Fischer Y, Garyantes T (2018) Improving the reliability and utility of streptozotocin-induced rat diabetic model. J Diabetes Res 2018:8054073. https://doi.org/10.1155/2018/8054073
Zhou H, Zhang S, Lv F et al (2019) Citrate-assisted efficient local delivery of naked oligonucleotide into live mouse brain cells. Cell Prolif 52:e12622. https://doi.org/10.1111/cpr.12622
Funding
This work was funded by the Croatian Science Foundation (IP-2018-01-8938 and IP-2014-09-4639). Research was co-financed by the Scientific Centre of Excellence for Basic, Clinical and Translational Neuroscience (project “Experimental and clinical research of hypoxic-ischemic damage in perinatal and adult brain”; GA KK01.1.1.01.0007 funded by the European Union through the European Regional Development Fund).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None.
Ethics committee approval
Not applicable.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Homolak, J., Perhoc, A.B., Knezovic, A. et al. Additional methodological considerations regarding optimization of the dose of intracerebroventricular streptozotocin A response to: “Optimization of intracerebroventricular streptozotocin dose for the induction of neuroinflammation and memory impairments in rats” by Ghosh et al., Metab Brain Dis 2020 July 21. Metab Brain Dis 36, 97–102 (2021). https://doi.org/10.1007/s11011-020-00637-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11011-020-00637-9